Roche launches Axelios gene sequencer to challenge Illumina's 70% market grip

Roche's new gene sequencer can complete whole-genome analysis in a single day, threatening Illumina's decades-long dominance in DNA sequencing.

Roche launched the AXELIOS 1 gene sequencer on Monday, a direct challenge to Illumina's 70% grip on the $7.3 billion gene sequencing market. The Swiss diagnostics giant aims to place 100 units in its debut year and generate more than 1 billion Swiss francs in annual revenue from the platform.

"AXELIOS 1 will deliver a disruptive sequencing solution that combines high accuracy with unprecedented speed and scalability," Matt Sause, chief executive officer of Roche Diagnostics, said in a statement. "In the future, AXELIOS 1 has the same potential to enable the next generation of clinical applications and unlock new frontiers in personalized healthcare."

The platform uses sequencing by expansion (SBX) technology, a novel approach that converts DNA into surrogate polymers called Xpandomers — 50 times longer than the original molecule — and reads them through a reusable complementary metal-oxide-semiconductor sensor containing millions of nanopores. The system can produce whole-genome results within hours, with reads of up to 1,500 base pairs, and handle both small-scale studies and large genomic projects on a single instrument. Roche has partnered with 10x Genomics for single-cell and spatial application kits and integrated Google DeepVariant for base-calling analysis, alongside an open-source bioinformatics suite called XOOS.

The launch comes more than a decade after Roche's failed $6.8 billion takeover attempt of Illumina in 2016. Illumina, which commands roughly 70% of the installed base for gene sequencers, has faced growing competition from Chinese manufacturer MGI Tech and newer entrants such as Pacific Biosciences. Roche's entry adds a well-capitalized rival with an existing diagnostics sales network spanning more than 150 countries.

How SBX Technology Works

The SBX chemistry encodes the sequence of a target nucleic acid molecule into a measurable surrogate polymer with high signal-to-noise reporters, improving accuracy in single-molecule sequencing. The platform's CMOS sensor module is reusable and designed for cost-efficient sequencing across different project sizes. Early-access users have demonstrated applications in oncology, genetics and infectious diseases, and the technology set a world record for fastest DNA sequencing technique, according to Roche. The company is offering library preparation kits alongside the free XOOS analysis suite. Multiple research applications have been tested as proof of principle since the SBX technology was unveiled in early 2025, including whole-genome sequencing, RNA-sequencing, single-cell RNA, spatial analysis and methylation detection.

What's at Stake for Illumina and Investors

Illumina's sequencing revenue totaled $4.5 billion in 2025, and the company's gross margins have come under pressure from MGI's lower-priced instruments. Roche's AXELIOS 1, with its same-day turnaround and flexible throughput, could accelerate pricing compression in the research segment before potentially moving into clinical diagnostics — a market where Illumina generates the bulk of its profit. Roche has secured endorsements from Broad Clinical Labs and the Hartwig Medical Foundation, with initial commercial shipments underway to the US, UK, Germany and France. The sequencing market is projected to grow at double-digit rates, according to DeciBio, providing room for multiple players, but Roche's scale and cross-selling capability make it a more formidable threat than smaller challengers. Roche shares trade at roughly 17 times forward earnings; any material revenue contribution from AXELIOS 1 is unlikely before 2027, analysts said.

This article is for informational purposes only and does not constitute investment advice.